Literature DB >> 12960131

Peroxiredoxins in breast carcinoma.

Peeter Karihtala1, Anne Mäntyniemi, Sang Won Kang, Vuokko L Kinnula, Ylermi Soini.   

Abstract

PURPOSE: Peroxiredoxins (Prxs) are a novel group of peroxidases containing high antioxidant efficiency and some of them having also effects on cell differentiation and apoptosis. The mammalian Prx family has six distinct members located in various subcellular locations, including peroxisomes and mitochondria, places where oxidative stress is most evident. EXPERIMENTAL
DESIGN: We examined immunohistochemically a large set of samples from patients with breast carcinoma and investigated associations with parameters such as tumor-node-metastasis classification, hormone receptor status, and patient survival. Three biopsies of healthy breast tissue were used as controls.
RESULTS: Expression of peroxiredoxins I, III, IV, and V was found in >or=80% of cases, whereas the expression of Prx II and VI was less frequent. Increased expression of Prx III was found to associate with the presence of progesterone (P = 0.02) and estrogen (P = 0.03) receptors, and Prxs IV (P = 0.009) and VI (P = 0.04) were overexpressed in progesterone receptor positive cases. Prx V was the only isoform that associated with items of tumor-node-metastasis classification, it was connected to a larger tumor size (P = 0.05) and positive lymph node status (P = 0.04). Prx V positivity was also connected with shorter survival (P = 0.04), whereas Prxs III (P = 0.002) and IV (P = 0.02) were related to better prognosis, probably resulting from their connection with a positive hormone receptor status.
CONCLUSIONS: In conclusion, we found that expression of peroxiredoxins, especially III, IV and V, is increased in breast malignancy, suggesting the induction of Prxs as response to increased production of reactive oxygen species in carcinomatous tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960131

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  80 in total

1.  Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma.

Authors:  Jintao Zhang; Kaijuan Wang; Jianzhong Zhang; Samuel S Liu; Liping Dai; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2011-05-03       Impact factor: 4.466

Review 2.  The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells.

Authors:  Lianqin Li; Ai-Qun Yu
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-21       Impact factor: 4.553

3.  Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.

Authors:  Anamika Basu; Hiya Banerjee; Heather Rojas; Shannalee R Martinez; Sourav Roy; Zhenyu Jia; Michael B Lilly; Marino De León; Carlos A Casiano
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

4.  Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins.

Authors:  Rui Tian; Li-Ming Wei; Ren-Yi Qin; Yan Li; Zhi-Yong Du; Wei Xia; Cheng-Jian Shi; Hong Jin
Journal:  Dig Dis Sci       Date:  2007-05-11       Impact factor: 3.199

5.  HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.

Authors:  R B Parmigiani; W S Xu; G Venta-Perez; H Erdjument-Bromage; M Yaneva; P Tempst; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-07       Impact factor: 11.205

Review 6.  Epigenetic regulation of peroxiredoxins: Implications in the pathogenesis of cancer.

Authors:  Suet-Hui Ow; Pei-Jou Chua; Boon-Huat Bay
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

7.  Downregulation of peroxiredoxin II suppresses the proliferation and metastasis of gastric cancer cells.

Authors:  Linjun Niu; Ang Liu; Wei Xu; Liang Yang; Wugang Zhu; Yuming Gu
Journal:  Oncol Lett       Date:  2018-07-25       Impact factor: 2.967

8.  Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.

Authors:  Jie Zhou; Weiwen Shen; Xiaojing He; Jing Qian; Shiyuan Liu; Guanzhen Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Large-scale analysis of protein expression changes in human keratinocytes immortalized by human papilloma virus type 16 E6 and E7 oncogenes.

Authors:  Mark A Merkley; Ellen Hildebrandt; Robert H Podolsky; Hilal Arnouk; Daron G Ferris; William S Dynan; Hubert Stöppler
Journal:  Proteome Sci       Date:  2009-08-23       Impact factor: 2.480

10.  Protein modifications as potential biomarkers in breast cancer.

Authors:  Hongjun Jin; Richard C Zangar
Journal:  Biomark Insights       Date:  2009-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.